Waldenström macroglobulinemia is a rare lymphoproliferative disorder, with an estimated 1,500 new cases reported in the United States each year. This malignancy, which accounts for 2% of non-Hodgkin lymphomas, is characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM). It is important for health care professionals involved in the care of patients with Waldenström macroglobulinemia to remain up to date in their knowledge of risk stra...

Complete surgical resection prior to immunochemotherapy may benefit patients with diffuse large B-cell lymphoma (DLBCL) under the age of 60, according to results from a subgroup analysis of the phase 3 PETAL trial. Unlike the treatment of solid tumors, the treatment of lymphoma focuses almost exclusively on systemic therapy. Surgical resection is generally only performed for diagnostic value, and little evidence exists regarding its impact on outcomes for patients with lymphoma. "Modern imaging ...

Glyphosate-based herbicides, such as Roundup®, are widely used in the United States in crops, gardens, and lawncare. Luoping Zhang, PhD, MS, Adjunct Professor at University of California, Berkeley, and colleagues revealed in a study that exposure to glyphosate increases an individual's chance of developing non-Hodgkin lymphoma (NHL). In this interview with i3 Health, Dr. Zhang shared insights about the implications of exposure to glyphosate-based herbicides and recommendations for avoiding expos...

Researchers report that glyphosate, the herbicide commonly found in Roundup® (Monsanto Technology, LLC), which is used as a pesticide on produce, significantly increases the risk of developing non-Hodgkin lymphoma (NHL) in humans. "Our analysis focused on providing the best possible answer to the question of whether or not glyphosate is carcinogenic," remarked the senior author of the paper, Lianne Sheppard, PhD, Professor of Environmental and Occupational Health Sciences and Biostatistics at th...

Researchers at the University of California, Los Angeles (UCLA) have become the first to successfully develop mature, cancer-killing T cells in a laboratory setting. The immune system's T cells fight infections; they also have the ability to fight cancer. Therapies that involve genetically engineering a patient's own T cells with a receptor that helps the T cells to recognize and destroy cancer cells have tremendous potential for certain types of cancer. One of these therapies is CAR T-cell ther...